- Dendreon to Hold Conference Call Today, March 13, 2008 at 11:00 AM ET -
SEATTLE, March 13 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today reported results for the year and quarter ended December 31, 2007. Revenues for the year ended December 31, 2007 were $743,000 compared to $273,000 for the year ended December 31, 2006. Revenues for the fourth quarter of 2007 were $28,000, compared to $86,000 for the same period in 2006.
The net loss for the year ended December 31, 2007 was $99.3 million, or $1.20 per share, compared to $91.6 million, or $1.27 per share for the year ended December 31, 2006. Net loss in the fourth quarter of 2007 was $27.0 million or $0.32 per share, compared to a net loss of $21.5 million, or $0.28 per share, for the same period in 2006. Dendreon's total operating expenses for the year ended December 31, 2007 were $102.4 million compared to $97.6 million in 2006. Net cash used in operating activities in 2007 was $82.6 million compared to $80.8 million in 2006.
As of December 31, 2007, Dendreon had approximately $120.6 million in
cash, cash equivalents, and short-term and long-term investments compared
to $121.3 million as of December 31, 2006.
-- The FDA agreed to amend the IMPACT (IMmunotherapy for Prostate
AdenoCarcinoma Treatment) Special Protocol Assessment (SPA),
accelerating the expected timeline for final results from the study by
approximately one year while maintaining comparable power to the
previous SPA. In addition, the FDA reconfirmed that either a positive
interim or final analysis of survival would support licensure and
enable Dendreon to amend the company's biologic
|SOURCE Dendreon Corporation|
Copyright©2008 PR Newswire.
All rights reserved